Joseph Friedman is a Psychiatry physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
998 Crooked Hill Road
Pilgrim Psychiatric Center Building 47 Third Floor
W Brentwood, NY 11717
Telephone
631-761-3607Registry record last updated 8 Jul 2007.
Clinical trials
- The Effect of Rasagiline on Cognition in Parkinson's Disease
Sponsor: Brown University
- Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Sponsor: Research Foundation for Mental Hygiene, Inc.
- Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia
Sponsor: Research Foundation for Mental Hygiene, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Gabapentinoids100%Pregabalin53%Gabapentin47%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2004–2007 per NIH RePORTER. The latest:
- Pimozide Augmentation of Clozapine in Schizophrenia
Icahn School of Medicine at Mount Sinai
FY2007$289,291R01MH067806 - Pimozide Augmentation of Clozapine in Schizophrenia
Icahn School of Medicine at Mount Sinai
FY2006$297,930R01MH067806 - PILOT STUDY OF ATOMOXETINE TO ENHANCE COGNITION IN PATIENTS WITH SCHIZOPHRENIA
Icahn School of Medicine at Mount Sinai
FY2006$6,434M01RR000071
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”